Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Liabilities and Shareholders Equity: 2019-2025

Historic Liabilities and Shareholders Equity for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $1.3 billion.

  • Beam Therapeutics' Liabilities and Shareholders Equity rose 11.93% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 billion, marking a year-over-year increase of 0.40%. This contributed to the annual value of $1.1 billion for FY2024, which is 24.38% down from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Liabilities and Shareholders Equity is $1.3 billion, which was down 5.76% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Liabilities and Shareholders Equity registered a high of $1.5 billion during Q4 2021, and its lowest value of $693.2 million during Q1 2021.
  • For the 3-year period, Beam Therapeutics' Liabilities and Shareholders Equity averaged around $1.3 billion, with its median value being $1.3 billion (2023).
  • As far as peak fluctuations go, Beam Therapeutics' Liabilities and Shareholders Equity spiked by 315.62% in 2021, and later declined by 24.38% in 2024.
  • Quarterly analysis of 5 years shows Beam Therapeutics' Liabilities and Shareholders Equity stood at $1.5 billion in 2021, then dropped by 9.00% to $1.3 billion in 2022, then rose by 8.79% to $1.5 billion in 2023, then declined by 24.38% to $1.1 billion in 2024, then climbed by 11.93% to $1.3 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.3 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.5 billion for Q1 2025.